MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Pacira Pharmaceuticals Inc-DE

Open

SectorGezondheidszorg

25.84 0.78

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

25.25

Max

26

Belangrijke statistieken

By Trading Economics

Inkomsten

160M

16M

Verkoop

19M

187M

K/W

Sectorgemiddelde

11.23

57.333

EPS

0.91

Winstmarge

8.566

Werknemers

788

EBITDA

165M

51M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+31.88% upside

Dividenden

By Dow Jones

Volgende Winsten

6 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-26M

1.2B

Vorige openingsprijs

25.06

Vorige sluitingsprijs

25.84

Technische score

By Trading Central

Vertrouwen

Very Strong Bullish Evidence

Pacira Pharmaceuticals Inc-DE Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 apr 2025, 23:45 UTC

Populaire aandelen

Stocks to Watch: CVS Health, UnitedHealth Group, Spire Global, Pacira BioSciences

2 jul 2024, 16:22 UTC

Belangrijke Marktbewegers

Pacira BioSciences Shares Tumble as FDA Approves Exparel Generic

Peer Vergelijking

Prijswijziging

Pacira Pharmaceuticals Inc-DE Prognose

Koersdoel

By TipRanks

31.88% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 34.29 USD  31.88%

Hoogste 65 USD

Laagste 21 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pacira Pharmaceuticals Inc-DE - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

8 ratings

3

Buy

4

Hold

1

Sell

Technische score

By Trading Central

25.135 / 26.65Steun & Weerstand

Korte Termijn

Very Strong Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Pacira Pharmaceuticals Inc-DE

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.